Table 1.
Baseline Characteristics Stratified by Physical Activity
| All Patients, N = 1356 | Physically Active, N = 347 | Physically Inactive, N = 1009 | P Value | |
|---|---|---|---|---|
| Demographics | ||||
| Mean age, y (SD) | 52.9 (17.4) | 49.7 (19.0) | 54.1 (16.7) | <0.001 |
| Female sex | 696 (51.3) | 149 (42.9) | 547 (54.2) | <0.001 |
| BMI, kg/m2 (SD) | 28.3 (5.6) | 26.7(4.5) | 28.9 (5.9) | <0.001 |
| Comorbidities | ||||
| CAD | 278 (20.5) | 63 (18.2) | 215 (21.3) | 0.21 |
| DM | 225 (16.6) | 28 (8.1) | 197 (19.5) | <0.001 |
| HTN | 577 (42.6) | 126 (36.3) | 451 (44.7) | 0.006 |
| SBP, mm Hg (SD) | 133.0 (17.4) | 133.1 (17.9) | 132.9 (17.3) | 0.86 |
| Hyperlipidemia | 411 (30.3) | 99 (28.5) | 312 (30.9) | 0.40 |
| Smoking history | 635 (46.8) | 156 (45.0) | 479 (47.5) | 0.42 |
| Active cancer | 245 (18.1) | 42 (12.1) | 203 (20.1) | 0.001 |
| NYHA class ≥ II | 781 (57.6) | 117 (33.7) | 664 (65.8) | <0.001 |
| High salt intake | 754 (55.6) | 164 (47.3) | 590 (58.5) | <0.001 |
| CKD | 97 (7.2) | 26 (7.5) | 71 (7.0) | 0.78 |
| Medications | ||||
| ASA | 282 (20.8) | 64 (18.4) | 218 (21.6) | 0.21 |
| ACEI/ARB | 418 (30.8) | 99 (28.5) | 319 (31.6) | 0.28 |
| β‐Blocker | 461 (34) | 110 (31.7) | 351 (34.8) | 0.30 |
| Statin | 410 (30.2) | 109 (31.4) | 301 (29.8) | 0.58 |
| Anticoagulant | 42 (3.1) | 8 (2.3) | 34 (3.4) | 0.32 |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASA, aspirin; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; NYHA, New York Heart Association; SBP, systolic blood pressure; SD, standard deviation.
Data are presented as n (%) unless otherwise noted.